Table 2.
Clinical, demographical, and electrodiagnostic data.
| Control | Anti-MAG | CIDP | d-CIDP | p | |
|---|---|---|---|---|---|
| Age (± SD) | 54.2 ± 19.37 | 68.2 ± 7.11 | 62.33 ± 13.48 | 54.67 ± 16.13 | 0.138 |
| (30–82) | (55–80) | (31–77) | (33–79) | ||
| Gender | |||||
| F | 7 (70%) | 2 (20%) | 4 (33.3%) | 2 (33.3%) | 0.153 |
| M | 3 (30%) | 8 (80%) | 8 (66.7%) | 4 (66.7%) | |
| Anti-MAG antibodies | |||||
| > 50,000 BTU | NA | 6 (60%) | NA | NA | |
| < 50,000 BTU | NA | 4 (40%) | NA | NA | |
|
Duration of symptoms* (Months, IQR) |
NA | 19.5 (7–36) | 6.5 (5–24.5) | 3 (3–5) | .011* |
| INCAT (± SD) | NA | 3.11 ± 2.26 | 3.92 ± 3.42 | 4.67 ± 4.63 | 0.116 |
| ONLS (± SD) | NA | 2.56 ± 2.00 | 3.08 ± 2.57 | 3.67 ± 4.08 | 0.441 |
| MRC (IQR) | NA | 60, (57.9–60) | 60, (54.9–60) | 55.8, (44.2–60) | 0.263 |
| EDX (± SD) | NA | 21.00 ± 4.77* | 16.00 ± 12.91 | 7.33 ± 3.72* | 0.035 |
| Height (± SD) | 168.70 ± 10.68 | 171.40 ± 8.19 | 170.83 ± 9.80 | 181.40 ± 9.60 | 0.126 |
| Weight (± SD) | 63.60 ± 9.69 | 75.40 ± 11.39 | 72.00 ± 18.16 | 77.83 ± 18.22 | 0.212 |
*Statistically significant difference
M male, F female, INCAT Inflammatory Neuropathy Cause and Treatment Group (INCAT) disability scale, IQR interquartile range, NA not applicable, ONLS Overall Neuropathy Limitations Scale, SD Standard deviation.